证券代码：688016 证券简称：心脉医疗 公告编号：2023-042 上海微创心脉医疗科技（集团）股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗"或"公 司"）第二届监事会第十五次会议（以下简称"本次会议"或"会议"）于2023 年8月24日在公司会议室以现场表决与通讯结合的方式在公司会议室召开。本次 会议通知及相关资料已于2023年8月14日以通讯方式送达全体监事。本次会议由 公司监事会主席CHENGYUN YUE女士召集并主持，会议应出席监事3名，实际出席 监事3名。本次会议的召集、召开方式符合相关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： （一）审议通过《公司2023年半年度报告及其摘要》 监事会认为：公司2023年半年度募集资金存放与实际使用情况符合《上市公 司监管指引第2号—上市公 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2023-032 上海微创心脉医疗科技（集团）股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 08 日(星期四) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 01 日(星期四) 至 06 月 07 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 irm@endovastec.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"） 已于 2023 年 3 月 30 日及 2023 年 4 月 28 日分别发布公司 2022 年度 报告及 2023 年第一 ...

Financial Performance - In Q1 2023, the company reported a revenue of ¥285,591,399.25, representing a year-on-year increase of 10.75%[13] - The net profit attributable to shareholders was ¥124,840,722.70, showing a slight increase of 1.10% compared to the same period last year[13] - Total revenue for Q1 2023 was CNY 285,591,399.25, an increase of 10.3% compared to CNY 257,879,693.03 in Q1 2022[48] - Net profit for Q1 2023 was CNY 123,553,343.99, slightly up from CNY 122,074,575.79 in Q1 2022, reflecting a growth of 1.2%[50] - Basic earnings per share for Q1 2023 was CNY 1.73, compared to CNY 1.72 in Q1 2022[51] Research and Development - R&D expenses totaled ¥60,844,478.10, up 43.51% year-on-year, accounting for 21.30% of the operating revenue, an increase of 4.86 percentage points[15] - The company plans to submit registration materials for 13 new products and has 7 products entering clinical trial phases within the year[15] - Research and development expenses for Q1 2023 were CNY 36,218,269.91, up from CNY 34,289,792.96 in Q1 2022, indicating a 5.6% increase[48] Market Expansion - The company expanded its overseas market presence to 25 countries, with overseas sales revenue increasing by 138% year-on-year[6] - The number of Castor branched aortic stent grafts implanted increased by 24.32% year-on-year, while Minos abdominal aortic stent grafts saw a 45.51% increase, and Reewarm PTX drug-coated balloon catheters grew by 62.54%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,159,243,634.08, an increase of 8.23% from the end of the previous year[5] - Total current assets reached RMB 1,418,277,564.28, an increase from RMB 1,294,342,713.72 at the end of 2022[36] - The company's cash and cash equivalents stood at RMB 1,070,704,082.25, up from RMB 976,893,164.69 at the end of 2022[33] - Total liabilities increased to RMB 288,423,366.04 from RMB 252,494,169.40 at the end of 2022[39] - The total equity attributable to shareholders was RMB 1,847,907,675.33, up from RMB 1,718,668,312.38 at the end of 2022[39] Cash Flow - The net cash flow from operating activities was ¥119,389,672.63, reflecting a decrease of 17.85% compared to the same period last year[13] - Cash flow from operating activities in Q1 2023 was CNY 325,268,253.52, an increase from CNY 293,795,410.32 in Q1 2022[52] - Net cash flow from operating activities was $119,389,672.63, a decrease of 17.8% compared to $145,322,872.72 in the previous period[54] - Total cash outflow from operating activities amounted to $205,878,580.89, up from $148,472,537.60, indicating a significant increase in operational expenses[54] Expenses - Total operating costs for Q1 2023 were CNY 145,144,980.49, up from CNY 122,556,913.84 in Q1 2022, representing a 18.4% increase[48] - Sales expenses for Q1 2023 were CNY 25,073,250.27, compared to CNY 20,123,974.33 in Q1 2022, marking a 24.6% increase[48] - Cash paid to employees was $67,772,259.07, compared to $51,107,792.74 previously, reflecting a 32.5% increase[54] - Cash paid for taxes was $32,682,998.65, down from $37,018,037.93, indicating a 11.0% decrease[54] Other Financial Metrics - The weighted average return on equity decreased to 7.00%, down 0.92 percentage points from the previous year[5] - The company reported a net loss of RMB 4,701.90 from non-current asset disposal due to unauthorized approvals or lack of formal documentation[26] - Government subsidies recognized in the current period amounted to RMB 2,622,312.75, closely related to the company's normal business operations[26] - The company did not execute any mergers or acquisitions during this reporting period, with net profit from merged entities remaining at CNY 0[43]

Financial Performance - The company's operating revenue for 2022 was ¥896,500,382.30, representing a 30.95% increase compared to ¥684,630,746.64 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥356,878,470.69, a 12.99% increase from ¥315,855,662.84 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥323,794,022.99, up 12.25% from ¥288,456,561.60 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥333,760,799.77, an increase of 11.16% compared to ¥300,252,679.31 in 2021[21]. - The total assets at the end of 2022 were ¥1,995,118,702.47, reflecting a 13.77% increase from ¥1,753,572,372.53 at the end of 2021[21]. - The net assets attributable to shareholders increased by 15.02% to ¥1,718,668,312.38 at the end of 2022, compared to ¥1,494,285,442.34 at the end of 2021[21]. - The basic earnings per share increased to 4.96 yuan, reflecting a growth of 12.98% year-on-year[22]. - The company's main business gross margin decreased to 75.18% in 2022 from 78.05% in 2021, indicating a decline influenced by product structure changes and raw material price fluctuations[103]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 23.00 per 10 shares, totaling approximately RMB 165.55 million, which represents 46.39% of the net profit attributable to shareholders for 2022[5]. - The company will not conduct capital reserve transfers or issue bonus shares as part of its profit distribution plan[5]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for the reporting period[197]. Research and Development - The R&D investment accounted for 19.22% of operating revenue, up by 1.18 percentage points from the previous year[22]. - The company reported a total R&D investment of ¥172,266,482.27, an increase of 39.51% compared to the previous year, accounting for 19.22% of operating revenue[75]. - The company submitted a total of 166 patent applications and received 80 new patent authorizations, bringing the total authorized patents to 249 as of December 31, 2022[33]. - The company has increased incentives for research and development personnel to attract more talent in this area[193]. - The company has developed a range of innovative medical devices, including a drug-coated balloon catheter and a multi-branch thoracic aortic stent, enhancing its product portfolio[87]. Market Expansion and Strategy - The company is focused on expanding its market presence and developing new products and technologies[20]. - The company plans to further develop its international market presence while maintaining product influence domestically[30]. - The company aims to improve operational efficiency and increase market share through targeted strategies[20]. - The company is exploring potential acquisitions to strengthen its product portfolio and market position[167]. - The company plans to expand its marketing network to enhance market share and product penetration, particularly in county-level hospitals in China[148]. Risks and Challenges - The company has detailed potential risks in its report, emphasizing the importance of investor awareness regarding future plans and strategies[6]. - The company faces risks related to the loss of core technical personnel, which could impact its ability to maintain technological leadership in the industry[94]. - The company operates in a highly competitive market, with significant pressure from multinational competitors like Medtronic and Boston Scientific, which could affect market share and profit margins[96]. - The company is exposed to procurement risks for essential raw materials, which could lead to increased costs and supply chain disruptions if domestic suppliers face difficulties[99]. Governance and Management - The company has a clear governance structure with specialized committees, including a strategy and development committee, audit committee, and nomination committee[155]. - The company held 10 board meetings throughout the year, all convened by the chairman[155]. - The supervisory board conducted 7 meetings during the reporting period, all chaired by the supervisory board chairman[157]. - The company has implemented a performance-oriented compensation policy, including project bonuses and performance bonuses, to align employee interests with corporate performance[193]. - The company maintains independence from its controlling shareholder in terms of business operations, assets, and financial management[155]. Employee and Workforce - The total number of employees reached 786, with a net increase of 126 employees, representing a growth rate of 19.09%[36]. - The company has 223 R&D personnel, making up 28.37% of the total workforce, with 60.10% of R&D staff holding master's degrees or higher[36]. - The average age of key personnel is around 41 years, indicating a balance of youth and experience[165]. - The company has a total of 9 doctoral graduates and 153 master's graduates among its employees[192]. Future Outlook - Future guidance indicates continued growth in revenue and profitability as the company leverages its innovative solutions[20]. - The company provided a positive outlook for the next fiscal year, projecting revenue growth of 20% to $600 million[167]. - The company plans to increase production capacity to meet growing market demand and optimize production processes to reduce costs[149]. - The company aims to enhance its core competitiveness and profitability by focusing on R&D, technology, manufacturing, and market expansion, with a goal of maintaining healthy growth in revenue and performance[145].

Financial Performance - The company's operating revenue for 2019 was approximately ¥333.73 million, representing a 44.39% increase compared to ¥231.13 million in 2018[18]. - The net profit attributable to shareholders for 2019 was approximately ¥141.76 million, a 56.38% increase from ¥90.65 million in 2018[18]. - The net cash flow from operating activities for 2019 was approximately ¥143.20 million, up 34.02% from ¥106.85 million in 2018[18]. - The total assets at the end of 2019 were approximately ¥1.16 billion, a 329.93% increase from ¥268.82 million at the end of 2018[18]. - The net assets attributable to shareholders at the end of 2019 were approximately ¥1.07 billion, a significant increase of 393.15% from ¥216.16 million at the end of 2018[18]. - The company achieved total revenue of ¥333,732,539.52, representing a year-on-year growth of 44.39%[91]. - The net profit attributable to the parent company was ¥141,755,858.84, an increase of 56.38% compared to the previous year[91]. - The sales revenue from the domestic market was ¥322,854,506.81, with a growth rate of 43.28% year-on-year[93]. - The gross profit margin for the main product category of arterial stents was 81.08%, an increase of 1.82 percentage points from the previous year[93]. - The company reported a significant increase in accounts receivable due to higher sales revenue, indicating strong demand for its products[148]. Research and Development - The company focuses on the research, production, and sales of interventional medical devices for aortic and peripheral vascular diseases, aiming to be a global leader in this field[23]. - The company has developed a comprehensive product line, including aortic stent graft systems and peripheral vascular stent systems, with a commitment to continuous innovation[23]. - The company has established a forward-looking R&D system to ensure continuous product innovation and efficient new product iteration[29]. - The company’s research and development strategy emphasizes producing one generation of products while developing another, ensuring a continuous pipeline of innovative products[50]. - The company’s innovative product development is expected to enhance its competitive edge in the increasingly fierce market[50]. - As of December 31, 2019, the company had 95 R&D personnel, accounting for 24.55% of total employees, with 56.84% holding master's degrees or higher[76]. - The company has invested a total of RMB 46.3 million in R&D during the reporting period, with ongoing projects including a multi-branch thoracic aortic stent system and drug balloon dilation catheter[73]. - The company submitted 32 patent applications and received 24 patent authorizations during the reporting period[81]. - The company is actively developing innovative products based on clinical needs and ongoing technology assessments[106]. Market Presence and Strategy - The company has established a strong market presence, covering 30 provinces and municipalities in China, and has collaborated with over 100 distributors[46]. - The company is focusing on expanding its marketing channels in second and third-tier cities, anticipating increased penetration of minimally invasive intervention treatments in these areas[46]. - The company operates on a distribution model, selling products to distributors who then sell to hospitals and medical institutions[58]. - The company expanded its market coverage by adding over 60 new hospitals, now reaching 300 hospitals with the Castor branched aortic stent and delivery system since its launch in 2017[110]. - The company plans to strengthen cooperation with leading regional clients globally and promote the certification of existing products in the EU and Asia-Pacific markets[185]. - The company will continue to strengthen its brand recognition in international markets to facilitate product entry into more countries and regions[185]. Financial Management and Governance - The company reported a government subsidy of approximately ¥15.98 million in 2019, compared to ¥8.24 million in 2018[20]. - The company plans to distribute a cash dividend of RMB 6.5 per 10 shares, totaling approximately RMB 46.79 million, based on a total share capital of 71.98 million shares as of December 31, 2019[168]. - The company commits to using at least 20% of the after-tax cash dividends received from the issuer in the previous fiscal year for stock repurchase if stock price stabilization measures are implemented[157]. - The company will prioritize cash dividends, ensuring that at least 20% of the distributable profits are allocated for cash dividends each year[167]. - The company’s profit distribution policy will maintain continuity and stability, considering industry characteristics and development stages[167]. - The company will enhance its governance structure and decision-making mechanisms to protect the interests of minority shareholders[163]. - The company has committed to not engaging in unfair benefit transfers or harming the interests of the company and its shareholders[178]. - The company will ensure compliance in related party transactions to protect the rights of the issuer and other shareholders[181]. - The company has a plan to enhance corporate governance and ensure compliance with its commitments[188]. Risks and Challenges - The company faced risks related to product price declines and technological updates, which could impact market performance[86][84]. - The company faces risks related to core competitiveness, including new product development and registration risks[114]. - The company’s procurement of raw materials is subject to foreign exchange fluctuations, which may impact operating performance[121]. Production and Operations - The production volume of arterial stents increased by 41.46% year-on-year, while the sales volume rose by 37.65%[95]. - The company aims to expand production capacity to meet increasing market demand and improve product quality while reducing costs[160]. - The company will continue to optimize existing business processes and implement information technology tools for efficient management[163]. - The company’s controlling shareholders committed to repurchase shares if any fraudulent issuance is confirmed, ensuring investor protection[141].

Financial Performance - The company's operating revenue for 2021 was approximately RMB 684.63 million, representing a year-on-year increase of 45.59% compared to RMB 470.25 million in 2020[4] - The net profit attributable to shareholders for 2021 was approximately RMB 315.86 million, reflecting a growth of 47.17% from RMB 214.61 million in 2020[4] - The net cash flow from operating activities for 2021 was approximately RMB 300.25 million, an increase of 38.09% compared to RMB 217.44 million in 2020[4] - The total assets of the company at the end of 2021 were approximately RMB 1.75 billion, a year-on-year increase of 27.43% from RMB 1.38 billion in 2020[4] - The net assets attributable to shareholders at the end of 2021 were approximately RMB 1.49 billion, reflecting a growth of 21.10% compared to RMB 1.23 billion in 2020[4] - The company's total operating costs were ¥150,281,289.69, up 52.91% year-over-year[85] - The gross profit margin decreased by 1.73 percentage points to 78.05%[86] - The company reported a net profit attributable to the parent company of ¥315,855,662.84, a year-over-year increase of 47.17%[107] Research and Development - The company is actively advancing the clinical trial phases for new products, including the next-generation Cratos branched aortic stent system and the Aegis abdominal aortic stent system, which have received necessary reports[10] - The company has a strong pipeline of innovative products, with ongoing upgrades to existing products and new technologies being developed to enhance its product line[9] - Research and development (R&D) investment totaled approximately ¥123.48 million, accounting for 18.04% of revenue, with a year-on-year increase of 48.20%[36] - The company has submitted a total of 140 patent applications, with 60 new patents granted during the reporting period, resulting in a total of 171 authorized patents as of December 31, 2021[36] - The company has launched 13 medical device products with registration certificates and 5 products with CE certification, establishing a comprehensive product line in the aortic and peripheral vascular intervention fields[32] - The company has initiated a series of R&D projects in the peripheral artery field, including peripheral milling tubes and vascular stents, which are progressing steadily[31] - The company emphasizes a market-oriented R&D mechanism to manage technological risks and ensure timely product updates and registrations[54] - The total R&D investment for the period was ¥123.48 million, reflecting a 48.20% increase from ¥83.32 million in the previous year[66] - The company is focusing on R&D investments, with new products like the Cratos branched aortic stent system and Aegis abdominal aortic stent system expected to enter clinical trials in 2022[156] Market Expansion - The company has expanded its international business, achieving over 100% growth in overseas sales revenue compared to the previous year, covering 18 countries and regions by the end of the reporting period[12] - The company has successfully expanded its international business, with sales covering 18 countries, including the UK and Brazil, where it achieved the first implant of its Minos abdominal aortic stent and delivery system[74] - The company achieved a market share ranking of second in China's aortic vascular intervention medical device market, only behind Medtronic, and first among domestic brands[59] - The company is actively pursuing market expansion strategies, targeting both domestic and international markets to increase its footprint[142] - The company aims to enhance product R&D and market expansion, focusing on the county-level hospital market to align with national healthcare resource strategies[130] Innovation and Technology - The company has received multiple awards for its technological innovations, including the Shanghai Science and Technology Progress Award and recognition as a "Manufacturing Industry Single Champion Product"[15] - The company is focused on continuous innovation and R&D investment, aiming to transition from technology followers to technology leaders in the medical device industry[16] - The company has developed advanced technologies such as ultra-low profile systems and precise release technology, enhancing the performance and safety of its vascular intervention products[33] - The company is exploring strategic partnerships to leverage synergies and enhance its competitive position in the market[143] - The company is committed to maintaining a competitive edge in the aortic and peripheral vascular intervention fields through continuous innovation and product development[129] Operational Efficiency - The company has established a complete quality management system in compliance with international standards, ensuring strict quality control across all operational stages[44] - The company has established a mature project evaluation system to track industry data and assess existing technologies to inform product development strategies[72] - The management team emphasized a commitment to maintaining high-quality standards while scaling production to meet growing demand[141] - The company has a strategic focus on expanding its market presence and improving operational efficiency through capacity expansion and cost reduction plans[157] Employee and Management - The company reported a total registered capital of 10,000 million RMB for Shanghai Blue Pulse and 5,500 million RMB for Shanghai Hongmai[151] - The total number of employees listed is 6, with a combined total compensation of RMB 1,800.35 million[167] - The company has a structured approach to employee compensation, with a focus on performance-based incentives[179] - The company has established a performance evaluation mechanism for senior management, linking their compensation to the achievement of operational goals[183] - The company reported a significant increase in R&D personnel, with key positions held by experienced professionals from various sectors, enhancing its innovation capabilities[141] Social Responsibility and Compliance - The company actively participates in social responsibility initiatives, including a poverty alleviation project in collaboration with the Gansu Yuanda Group[195] - The company has maintained compliance with information disclosure regulations, ensuring accurate and timely communication with investors[163] - The company has not been classified as a key pollutant discharge unit by environmental protection authorities[187] - The company received ISO 50001:2018 energy management system certification, recognizing its achievements in energy conservation and utilization[191] Future Outlook - Future plans include the application of smart manufacturing technologies to improve production efficiency and scale[132] - Future guidance indicates a projected revenue growth of 20% year-over-year, driven by increased market demand and successful product launches[143] - Overall, the company remains optimistic about its growth trajectory, supported by a robust pipeline of innovative products and strategic initiatives[143]

Product Development and Innovation - The company has developed the first domestically produced abdominal aortic stent and the only approved intraoperative stent system for thoracic aortic dissection surgery in China[6]. - The company has successfully transitioned from technology following to technology leading, focusing on independent intellectual property product development[6]. - The company has developed the Castor branched stent system, the world's first approved device for treating aortic arch lesions, and the Minos abdominal aortic stent, which has the smallest delivery system outer sheath diameter in the domestic market[22]. - The company has initiated the development of multiple products in the peripheral venous field, including the iliac vein stent system, which is currently in clinical stages, with expected product registrations between 2023 and 2025[23]. - The company has introduced new products, including the Reewarm PTX drug balloon dilation catheter, which received medical device registration during the reporting period[110]. - The company is actively pursuing new product launches in the coming years to support its growth strategy[189]. Market Growth and Financial Performance - The aortic intervention medical device market in China is projected to grow from CNY 1.03 billion in 2017 to CNY 1.95 billion by 2022, with a compound annual growth rate (CAGR) of 13.5%[16]. - The peripheral vascular intervention medical device market in China is expected to increase from CNY 3.01 billion in 2017 to CNY 7.12 billion by 2022[19]. - The company achieved operating revenue of ¥470,252,334.82, representing a 40.91% increase compared to the same period last year[51]. - Operating profit reached ¥249,934,700, reflecting a 52.15% year-over-year growth[64]. - Net profit attributable to shareholders was ¥214,612,900, up 51.40% from the previous year[64]. - Revenue from the aortic and peripheral vascular intervention industry reached ¥465,064,486.44, an increase of 41.37% year-on-year, with a gross margin of 79.78%[100]. Research and Development - The company has established a forward-looking R&D system based on product lifecycle management to ensure continuous product innovation and efficient new product iteration[12]. - The company has strengthened its R&D team, increasing the number of R&D personnel to 157, with 93 holding master's degrees or higher, representing 59.24% of the R&D team[31]. - Research and development expenses totaled ¥83,318,885.43, accounting for 17.72% of operating revenue, with a year-over-year increase of 37.29%[55][65]. - The company filed for 40 new invention patents and obtained 2, bringing the total to 197 applications and 74 granted[54]. - The company aims to enhance its R&D and innovation capabilities to provide cost-effective medical solutions for patients with aortic and peripheral vascular diseases[144]. Sales and Marketing Strategy - The company primarily uses a distribution model for sales, where products are sold to distributors who then supply hospitals[11]. - The company has shifted its marketing strategies to online platforms during the pandemic, conducting various online academic activities to maintain engagement with medical professionals[39]. - The company aims to enhance its marketing network coverage and regional competitive advantages to expand market share and improve product penetration[124]. - The company plans to enhance its market presence by developing county-level hospitals and recruiting skilled technical and sales personnel to support product sales and brand promotion[189]. Compliance and Risk Management - The company has a high entry barrier in the medical device industry due to strict regulatory standards and the long development cycle of 5-10 years for Class III medical devices[20]. - The company faces risks related to the lengthy product registration process, which may delay the launch of new products and adversely affect operational performance[42]. - The company is focused on maintaining compliance with stringent regulatory standards and enhancing its quality management system[62]. - The company faces risks related to product price declines and management of distributors, which could impact brand reputation[72][73]. International Expansion - The company has expanded its international market presence, with products like Minos and Hercules achieving clinical implantation in nine European countries, including Poland, Greece, and Germany[33]. - The international business has expanded, with products implanted in 13 countries and significant sales growth compared to last year[67]. - The company will strengthen cooperation with leading regional clients globally to promote its products in mainstream markets such as the EU and Asia-Pacific[147]. Financial Management and Profit Distribution - The company reported a cash dividend of 9.0 CNY per 10 shares for the year 2020, totaling 64,780,332.30 CNY, which represents 30.18% of the net profit attributable to ordinary shareholders[166]. - The company is committed to maintaining a stable profit distribution policy, with cash dividends prioritized over stock distributions[131]. - The company has established a profit distribution policy to ensure a stable and transparent dividend mechanism for shareholders[165]. - The company plans to maintain a minimum cash dividend ratio of 40% during its mature phase when significant capital expenditures are planned[165]. Operational Efficiency - The company’s procurement management involves a centralized approach with a comprehensive evaluation of suppliers to ensure quality and compliance[9]. - The company’s cash flow from operating activities was ¥217,439,812.91, a 51.84% increase compared to the previous year[51]. - The company’s financial expenses decreased by 16.17%, improving overall financial performance[51]. - The increase in inventory is primarily attributed to the expansion of production scale during the reporting period[184]. - The company will expand its production scale to meet the growing market demand as product sales increase[147].

证券代码：688016 证券简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|------------------------------|--------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | √其他 2022 | 年第一季度报告业绩电话会 | | 参与单位名称 及人员姓名 | 108 家机构 140 | 名参与人员，详见附件清单（排名不分先后） | | 时间 | 2022 年 4 月 30 日 | | | 地点 | 电话会议 | | | 上市公司接待 | | 朱清（董事兼总经理）、邱根永（副总经理兼董事会秘书）、 | | 人员姓名 | | 李春芳（财务总监）、刘昊（治疗方案推广资深总监） | | | | 一、问：目前， ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥205,447,495.78, representing a year-on-year increase of 38.92%[7] - The net profit attributable to shareholders for Q3 2022 was ¥85,847,001.01, reflecting a year-on-year growth of 31.51%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥70,922,070.24, with a year-on-year increase of 32.96%[7] - Total operating revenue for the first three quarters of 2022 reached ¥664,247,489.74, a 30.2% increase from ¥510,158,422.03 in the same period of 2021[38] - Net profit for the third quarter of 2022 was ¥297,871,534.21, compared to ¥248,832,017.44 in the same quarter of 2021, representing a 19.7% increase[40] - Basic earnings per share for the third quarter of 2022 were ¥4.18, up from ¥3.47 in the same quarter of 2021, indicating a 20.4% increase[43] Research and Development - The total R&D investment for Q3 2022 was ¥42,246,946.26, which is an increase of 41.82% compared to the same period last year[11] - R&D investment accounted for 20.56% of operating revenue, an increase of 0.42 percentage points year-on-year[11] - Research and development expenses for the first three quarters of 2022 totaled ¥88,176,367.06, compared to ¥67,040,191.51 in the same period of 2021, marking a 31.5% increase[38] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,893,217,628.66, an increase of 7.96% compared to the end of the previous year[11] - The equity attributable to shareholders at the end of the reporting period was ¥1,661,667,699.27, reflecting an increase of 11.20% year-on-year[11] - The company's cash and cash equivalents decreased to RMB 1,040,567,606.76 from RMB 1,243,238,037.98 in the previous year, reflecting a decline of approximately 16.3%[29] - Accounts receivable increased to RMB 84,001,150.65, up from RMB 73,201,434.59, representing a growth of about 15%[29] - Inventory rose to RMB 133,392,734.72, compared to RMB 106,917,364.12, indicating an increase of approximately 24.7%[29] - The company's non-current assets totaled RMB 580,704,565.10, significantly up from RMB 294,949,685.80, marking an increase of around 96.8%[32] - Current liabilities decreased to RMB 143,522,131.37 from RMB 162,053,557.95, a reduction of about 11.4%[32] - Total liabilities decreased to ¥206,008,911.10 from ¥231,472,775.49, a reduction of approximately 11%[38] Cash Flow - The company reported a net cash flow from operating activities of ¥263,544,986.98 for the year-to-date, which is an increase of 17.84% compared to the same period last year[11] - The cash inflow from operating activities for the first three quarters of 2022 was RMB 765,900,437.99, an increase of 30.3% compared to RMB 587,186,784.48 in the same period of 2021[47] - The net cash flow from operating activities for the first three quarters of 2022 was RMB 263,544,986.98, up from RMB 223,648,012.35 in 2021, reflecting a growth of 17.8%[47] - The cash inflow from investment activities in the first three quarters of 2022 was RMB 2,033,836,685.94, significantly higher than RMB 716,982,478.55 in the same period of 2021, marking an increase of 184.5%[48] - The net cash flow from investment activities for the first three quarters of 2022 was negative RMB 323,228,387.03, an improvement from negative RMB 575,054,145.57 in 2021[48] - The cash outflow for purchasing fixed assets and other long-term assets in the first three quarters of 2022 was RMB 159,834,693.14, compared to RMB 42,036,624.12 in 2021, indicating a substantial increase[48] - The cash outflow from financing activities in the first three quarters of 2022 was RMB 159,755,427.87, compared to RMB 72,089,568.88 in 2021, showing an increase of 121.5%[48] Strategic Initiatives - The company held a board meeting on July 25, 2022, to approve plans for issuing A-shares to specific investors, indicating a strategic move for capital raising[26] - The company plans to implement a shareholder return plan for the next three years (2022-2024), focusing on dividend distribution[26] - The company expects continued growth in sales and profitability driven by increased sales scale and non-recurring gains[16]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the first half of 2022 was approximately ¥458.80 million, representing a 26.64% increase compared to ¥362.27 million in the same period last year[23]. - The net profit attributable to shareholders for the same period was approximately ¥215.04 million, up 16.42% from ¥184.70 million year-on-year[23]. - The net cash flow from operating activities increased by 36.88% to approximately ¥229.69 million, compared to ¥167.80 million in the previous year[23]. - The company has set a revenue guidance of 2.5 billion RMB for the full year 2022, indicating a growth target of 20%[1]. - Operating profit reached 250.5 million yuan, up 16.16% compared to the same period last year[77]. - The net profit attributable to shareholders was 215.04 million yuan, reflecting a growth of 16.42% year-on-year[77]. - The total revenue for peripheral products reached CNY 53.1 million, with a significant increase from CNY 43.34 million in the previous period, reflecting a growth of approximately 22.4%[63]. Research and Development - Research and development expenses accounted for 12% of total revenue, reflecting a commitment to innovation and new technology[1]. - The R&D investment as a percentage of operating revenue was 13.06%, a slight decrease of 0.62 percentage points from 13.68% in the previous year[24]. - R&D investment totaled ¥59,933,115.43, representing a 20.92% increase compared to the previous year, accounting for 13.06% of operating revenue[58][59]. - The R&D personnel count increased to 215, representing 27.81% of the total workforce, with an average salary of CNY 12.83 million, up from CNY 10.94 million in the previous year[66]. - The company submitted 99 patent applications during the reporting period, with 37 patents granted, bringing the total to 208 patents[55]. - The company has developed the first domestically produced abdominal aortic stent graft and the only approved intraoperative stent system for thoracic aortic dissection surgery in China[29]. - The company emphasizes innovation and has transitioned from technology following to technology leading in the medical device sector[29]. Market Expansion - User data indicates a 20% increase in the number of active users, reaching 500,000 by June 30, 2022[1]. - Market expansion efforts include entering three new international markets by the end of 2022[1]. - The company has expanded its international market presence, with products sold in 21 countries, including successful implantations in the UK and Brazil[73]. - The company holds a 32.4% market share in thoracic aortic surgeries in 2021, ranking first in the field[47]. - The domestic market share for thoracic aortic products reached 60.2%, indicating significant progress in import substitution[47]. Operational Challenges - The company faced significant operational challenges due to the severe COVID-19 pandemic in Shanghai and other regions, impacting R&D, production, sales, and delivery[23]. - The company established an emergency response team to ensure production supply during the Shanghai COVID-19 outbreak, implementing closed management for frontline staff to maintain operations[87]. - The capitalized R&D investment decreased by 19.95% due to delays in clinical trials caused by the pandemic[60]. Corporate Governance and Compliance - The company emphasized its commitment to maintaining high standards of corporate governance and transparency[1]. - The company has established an environmental management system (ISO 14001) and obtained certification to promote environmentally friendly practices[132]. - The company strictly adhered to national and local pollution discharge standards, ensuring that wastewater discharge met compliance requirements[130]. - The company has not reported any instances of exceeding pollution discharge limits during the reporting period[133]. Risks and Challenges - The management highlighted potential risks related to regulatory changes and market competition[1]. - The company is at risk of losing its competitive edge if it fails to keep pace with technological advancements in the rapidly evolving medical device industry[94]. - The company faces risks related to product price declines if it fails to keep pace with industry developments and technological innovations[97]. - There is a risk associated with the management of distributors, which could impact brand reputation and sales if not properly managed[98]. Shareholder Commitments and Policies - The company has committed to not providing financial assistance or loans to incentive recipients for acquiring restricted shares[138]. - The company will ensure that all related party transactions are conducted at market prices to protect shareholder interests[167]. - The company promises to maintain a stable profit distribution policy, with cash dividends accounting for at least 20% of the distributable profits each year[190]. - The company will prioritize cash dividends over stock dividends when conditions allow[191]. - The company will publicly explain any failure to implement share repurchase measures and apologize to shareholders if commitments are violated[180].